AD Biotech Appoints Four New Board Members to Strengthen Expertise in Investment, Global Management, Law, and Pharmaceuticals

AD Biotech (179530) is reinforcing its management foundation for business expansion by appointing new board members who are experts in investment, global management, law, and pharmaceuticals.

AD Biotech announced on August 11 that all agenda items to appoint two new inside directors and two new independent directors were approved as originally proposed at its general shareholders’ meeting held on the same day. The newly appointed board members are inside directors Hwang Manhoe and An Mansoo, and independent directors Lim Taehyeok and Jang Kiho.

The company explained that this board restructuring aims to enhance its capabilities in investment and management while also securing expertise in global business, law, and the pharmaceutical sector. Based on this, AD Biotech plans to further advance its existing immuno-antibody technology and accelerate the expansion of new businesses and overseas markets.

Inside director Hwang Manhoe previously served as Head of Strategic Planning at Paratech and as CEO of TSI Investment. He is expected to leverage his experience in investment and strategic planning to assist in establishing AD Biotech's mid- to long-term growth strategies, attracting investments, and enhancing management efficiency.

Inside director An Mansoo is a management expert who has served as Head of Division at Osung LST, head of Dasan Vietnam branch, and CEO of Korea Topron. The company expects that, based on his extensive domestic and international business experience, he will contribute to strengthening AD Biotech’s global business expansion, enhancing its network, and improving its management and operational processes.

Expertise in the legal sector has also been newly added to the board. Independent director Lim Taehyeok is currently a partner attorney at Yujun Law Firm. He also has experience in legislative work in the logistics and transportation sector as a national legislative advisor at the Korea Legislation Research Institute.

AD Biotech plans to utilize Lim's legal expertise to proactively respond to potential legal risks that may arise during business expansion and to strengthen its compliance and legal management systems.

Independent director Jang Kiho previously worked as a researcher at Whanin Pharmaceutical, was CEO of Daehak Pharmacy, and is currently CEO of Jeongmun Daehak Pharmacy. Based on his experience accumulated in the pharmaceutical and pharmacy sectors, he is expected to provide expertise in bio-pharmaceutical R&D and the promotion of new healthcare businesses.

Leveraging the new board structure, AD Biotech aims to fortify its business competitiveness using its existing immuno-antibody technology, while also entering new business fields such as digital healthcare.

In particular, the company believes that securing expertise in diverse fields such as investment and strategic planning, global management, law, and pharmaceuticals on the board will enhance decision-making capabilities for business diversification and global market expansion.

An official from AD Biotech said, “By appointing experts with competencies in each field to the board, we aim to further solidify the company’s growth foundation,” adding, “Based on our competitive edge in immuno-antibody technology, we will accelerate business diversification and global market expansion to enhance corporate value.”

This content was produced with the assistance of AI translation services.